A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma.

Trial Profile

A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2013

At a glance

  • Drugs Vorinostat (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MESO-02
  • Most Recent Events

    • 04 Jan 2013 Planned number of patients changed from 140 to 24 as reported by UKCRN.
    • 25 Jan 2012 Planned end date 1 Sep 2014 added as reported by UKCRN.
    • 25 Jan 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by UKCRN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top